In our study, we used FAK, ERK and NF-κB inhibitors to treat liver cancer cells, in which blockade of FAK/ERK/NF-κB signaling significantly suppressed the cell proliferation or migration of high stiffness cultured liver cancer cells, suggesting the crucial role of FAK/ERK/NF-κB signals in high stiffness induced liver cancer development. This evidence concerns the gene NFKB1 and liver cancer.